Analysis of S100 protein in the duodenal juice collected by oral endoscopy to detect early stage pancreatic cancers: Accompanying research for sample preservation methods

Analysis of S100 protein in the duodenal juice collected by oral endoscopy to detect early stage pancreatic cancers: Accompanying research for sample preservation methods - Analysis of S100 protein in the duodenal juice collected by oral endoscopy to detect early stage pancreatic cancers: Accompanying research for sample preservation methods

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049358

Enrollment

Registered

2022-11-01

Start date

2022-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

At the beginning of the endoscopy, the duodenum is entered within a few minutes and we collect the duodenal juice. The duodenal juice is collected within 3 minutes. Aspirate 45ul of the duodenal fluid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer patients 1) Aged 50 or more 2) Patients who undergo preoperative screening upper gastrointestinal endoscopy or endoscopic ultrasonography (EUS) for the assessment of pancreatic cancer 3) Written informed consent 4) Patients without definite malignant diseases in upper gastrointestinal lesion except pancreatic cancer 5) Patients who have undergone no surgery in gastrointestinal lesion 6) Patients without malignant disease in bile duct The patients who undergo physical examination 1) Aged 50 or more. 2) Patients proven to have normal pancreas by EUS 3) Patients who undergo screening upper gastrointestinal endoscopy for their pancreatic diseases 4) Written informed consent 5) Patients without definite malignant diseases in upper gastrointestinal lesion except pancreatic cancer 6) Patients who have undergone no surgery in gastrointestinal lesion, such as gastrectomy, pancreatoduodenectomy and so on. 7) Patients without malignant disease in bile duct

Exclusion criteria

Exclusion criteria: 1) They have no drug hypersensitivity. 2) The doctor-in-charge figures them to be suitable for this study.

Design outcomes

Primary

Measure	Time frame
The S100 protein concentration in the duodenal juice to detect patients with pancreatic cancers	—

Countries

Japan

Contacts

Public ContactNoboru Ideno

Graduate School of Medical Sciences, Kyushu University Department of Surgery and Oncology

ideno.noboru.033@m.kyushu-u.ac.jp092-631-2920

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026